flagyl leggangastíll 500 mg
sanofi-aventis norge as - metronidazolum inn - leggangastíll - 500 mg
ovestin leggangastíll 0,5 mg
aspen pharma trading limited - estriolum inn - leggangastíll - 0,5 mg
pinex endaþarmsstíll 500 mg
teva b.v.* - paracetamolum inn - endaþarmsstíll - 500 mg
pevaryl krem + leggangastíll (10 mg/g + 150 mg)
trimb healthcare ab - econazolum nítrat; econazolum nítrat - krem + leggangastíll - (10 mg/g + 150 mg)
pevaryl depot krem + leggangastíll (1% + 150 mg)
trimb healthcare ab - econazolum nítrat; econazolum nítrat - krem + leggangastíll - (1% + 150 mg)
pevaryl depot leggangastíll 150 mg
trimb healthcare ab - econazolum nítrat - leggangastíll - 150 mg
ceplene
laboratoires delbert - histamín díhýdróklóríð - kyrningahvítblæði, mergbólga, bráð - Ónæmisörvandi, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). verkun ceplene hefur ekki verið sýnt að fullu hjá sjúklingum eldri en 60 ára.
eplerenon krka filmuhúðuð tafla 50 mg
krka, d.d., novo mesto - eplerenonum inn - filmuhúðuð tafla - 50 mg
eplerenon krka filmuhúðuð tafla 25 mg
krka, d.d., novo mesto - eplerenonum inn - filmuhúðuð tafla - 25 mg
yervoy
bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - Æxlishemjandi lyf - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 og 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.